ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
근경직 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 연평균 성장률(CAGR) 8.8%로 63억 7,000만 달러로 성장할 것입니다. 예측 기간의 성장은 환자 중심의 의료 개발, 유통 채널 확대, 삶의 질 향상에 대한 집중, 표적 약물전달 시스템 개발, 바이오마커 발굴 등에 기인합니다. 예측 기간의 주요 동향으로는 가치 기반 상환 모델 채택, 인공지능과 머신러닝 기술의 통합, 원격의료 및 원격 모니터링 기술 채택, 신경 자극 기술, 재생의료 접근법 등이 있습니다.
향후 5년간 성장률 8.8%라는 예측은 지난번 예측보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰로 인해 프랑스와 스웨덴에서 개발된 보툴리눔톡신 주사와 바클로펜 척수강 내 펌프의 가격이 급등하고, 이로 인해 이동 관리가 저하되고 재활 치료 비용이 증가하여 미국의 환자 치료에 지장을 초래할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
근골격계 질환의 유병률 증가는 근경직 시장의 성장을 촉진할 것으로 예상됩니다. 근골격계 장애는 근육, 뼈, 관절에 영향을 미치며, 종종 통증, 뻣뻣함, 운동 제한을 유발합니다. 이러한 장애의 증가 요인으로는 인구의 고령화, 앉아서 생활하는 생활습관, 만성질환의 유병률 증가 등이 있습니다. 근경직 치료는 통증을 줄이고, 이동성을 높이고, 합병증을 예방하고, 환자의 전반적인 삶의 질과 기능적 능력을 향상시키는 것을 목표로 합니다. 예를 들어, Lancet지가 2023년 11월에 발표한 연구에 따르면, 2020년에는 전 세계적으로 4억 9,400만 명이 근골격계 질환을 경험하고 2050년에는 115% 증가할 것으로 예측했습니다. 또한, 암젠은 2022년 5월 골다공증으로 인한 골절이 2018년 190만 건에서 2020년에는 320만 건으로 68% 증가할 것으로 예상했습니다. 이러한 근골격계 질환의 유병률 증가가 근경직 시장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 근경직 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 근경직 시장 : 성장률 분석
세계의 근경직 시장 실적 : 규모와 성장, 2019-2024
세계의 근경직 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 근경직 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 근경직 시장 : 약제 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
바클로펜
보툴리눔톡신(보톡스)
디아제팜
댄 다랑어 렌 나트륨
기타 약물
세계의 근경직 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
근육내
기타 루트
세계의 근경직 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 근경직 시장 : 하위 세분화 바클로펜(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구 바클로펜
척수내 바클로펜(펌프)
세계의 근경직 시장 : 하위 세분화 보툴리눔톡신(보톡스)(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
보톡스(보툴리눔톡신(보톡스) A형)
디스포트(보툴리눔톡신(보톡스) A형)
제오민(A형 보툴리눔톡신(보톡스))
미오브록크(보툴리눔톡신(보톡스) B형)
세계의 근경직 시장 : 하위 세분화 디아제팜(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구 디아제팜
주사용 디아제팜
세계의 근경직 시장 : 하위 세분화 댄 다랑어 렌 나트륨(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구 댄 다랑어 렌
주사용 댄 다랑어 렌
세계의 근경직 시장 : 하위 세분화 기타 약제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
치자니진
클로니딘
가바펜틴
기타 근이완제
선택적 세로토닌 재흡수 억제제(SSRI)
제7장 지역별·국가별 분석
세계의 근경직 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 근경직 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
근경직 시장 : 경쟁 구도
근경직 시장 : 기업 개요
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Teva Pharmaceutical Industries Ltd.
Boston Scientific Corporation
Sun Pharmaceutical Industries Ltd.
Ipsen Pharma
Hikma Pharmaceuticals plc
Endo Pharmaceuticals Inc.
Lupin Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc.
Mallinckrodt Pharmaceuticals
Neurocrine Biosciences Inc.
Merz Pharmaceuticals GmbH
Beximco Pharmaceuticals Ltd.
ANI Pharmaceuticals Inc.
Taj Pharmaceuticals Limited
Revance Therapeutics Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
근경직 시장 2029 : 새로운 기회를 제공하는 국가
근경직 시장 2029 : 새로운 기회를 제공하는 부문
근경직 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Muscle spasticity is a condition marked by an abnormal increase in muscle tone or stiffness that can disrupt movement and speech. It typically arises from damage to the brain or spinal cord that affects the control of voluntary muscle movements.
The main types of drugs used to treat muscle spasticity include baclofen, botulinum toxin, diazepam, dantrolene sodium, and others. These drugs can be administered via various routes, such as oral and intramuscular. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The muscle spasticity market research report is one of a series of new reports from The Business Research Company that provides muscle spasticity market statistics, including the muscle spasticity industry global market size, regional shares, competitors with muscle spasticity market share, detailed muscle spasticity market segments, market trends, and opportunities, and any further data you may need to thrive in the muscle spasticity industry. These muscle spasticity market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The muscle spasticity market size has grown strongly in recent years. It will grow from $4.19 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing investments in research and development, expansion of clinical indications, favorable regulatory approvals and reimbursement policies, increasing emphasis on adopting a multimodal approach, and increasing prevalence of multiple sclerosis.
The muscle spasticity market size is expected to see strong growth in the next few years. It will grow to $6.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing focus on developing patient-centric care, expansion of distribution channels, focus on improving quality of life, focus on developing targeted drug delivery systems, and discovery of biomarkers. Major trends in the forecast period include adoption of value-based reimbursement models, integration of artificial intelligence and machine learning technologies, adoption of telehealth and remote monitoring technologies, neurostimulation techniques, and regenerative medicine approaches.
The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. patient care by inflating prices of botulinum toxin injections and intrathecal baclofen pumps developed in France and Sweden, resulting in reduced mobility management and higher rehabilitation therapy expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of musculoskeletal disorders is expected to boost the growth of the muscle spasticity market. Musculoskeletal disorders affect the muscles, bones, and joints, often leading to pain, stiffness, and restricted movement. Factors contributing to the rise in these disorders include aging populations, sedentary lifestyles, and a higher incidence of chronic conditions. Muscle spasticity treatments aim to reduce pain, enhance mobility, prevent complications, and improve the overall quality of life and functional abilities of patients. For example, a study published by The Lancet in November 2023 estimated that 494 million people worldwide experienced musculoskeletal disorders in 2020, with a projected increase of 115% by 2050. Additionally, Amgen reported in May 2022 that fractures due to osteoporosis are expected to rise by 68%, from 1.9 million in 2018 to 3.2 million by 2040. This growing prevalence of musculoskeletal disorders is driving the muscle spasticity market.
Key players in the muscle spasticity market are focusing on developing oral suspensions to treat muscle spasms caused by conditions such as multiple sclerosis and spinal cord injuries. Oral suspensions are liquid medications with active ingredients dispersed for oral consumption. For instance, ANI Pharmaceuticals, a US-based pharmaceutical company, introduced baclofen oral suspension in April 2024. This product, a generic version of Fleqsuvy, is designed to treat muscle spasms by helping to relax the muscles in conditions such as multiple sclerosis and spinal cord injuries.
In January 2022, Amneal Pharmaceuticals Inc., a US-based pharmaceutical manufacturer, acquired the baclofen franchise from Saol Therapeutics, including products such as Lioresal and Lyvispah. This $83.5 million acquisition aims to strengthen Amneal Pharmaceuticals' neurology portfolio and enhance its presence in the institutional market. It also supports Amneal's entry into the biosimilar market, with expected revenue growth from the baclofen franchise by 2025. Saol Therapeutics is a US-based company specializing in developing treatments for limb spasticity and pain related to knee osteoarthritis.
Major companies operating in the muscle spasticity market are F. Hoffmann-La Roche AG, AbbVie Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Neurocrine Biosciences Inc., Merz Pharmaceuticals GmbH, Beximco Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Taj Pharmaceuticals Limited, Revance Therapeutics Inc., Acorda Therapeutics Inc., Mylan N.V., Camber Pharmaceuticals Inc., Saol Therapeutics Inc., Zydus Cadila
North America was the largest region in the muscle spasticity market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle spasticity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the muscle spasticity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The muscle spasticity market consists of revenues earned by entities by providing services such as pharmaceutical treatments, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle spasticity market also includes sales of tizanidine, gabapentin, and pregabalin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Muscle Spasticity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on muscle spasticity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for muscle spasticity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The muscle spasticity market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Baclofen; Botulinum Toxin; Diazepam; Dantrolene Sodium; Other Drugs
2) By Route Of Administration: Oral; Intramuscular; Other Routes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Baclofen: Oral Baclofen; Intrathecal Baclofen (Pump)
2) By Botulinum Toxin: Botox (Botulinum Toxin Type A); Dysport (Botulinum Toxin Type A); Xeomin (Botulinum Toxin Type A); Myobloc (Botulinum Toxin Type B)
3) By Diazepam: Oral Diazepam; Injectable Diazepam
4) By Dantrolene Sodium: Oral Dantrolene; Injectable Dantrolene
5) By Other Drugs: Tizanidine; Clonidine; Gabapentin; Other Muscle Relaxants; Selective Serotonin Reuptake Inhibitors (SSRIs)
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Muscle Spasticity Market Characteristics
3. Muscle Spasticity Market Trends And Strategies
4. Muscle Spasticity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Muscle Spasticity Growth Analysis And Strategic Analysis Framework
5.1. Global Muscle Spasticity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Muscle Spasticity Market Growth Rate Analysis
5.4. Global Muscle Spasticity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Muscle Spasticity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Muscle Spasticity Total Addressable Market (TAM)
6. Muscle Spasticity Market Segmentation
6.1. Global Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Baclofen
Botulinum Toxin
Diazepam
Dantrolene Sodium
Other Drugs
6.2. Global Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intramuscular
Other Routes
6.3. Global Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Muscle Spasticity Market, Sub-Segmentation Of Baclofen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Baclofen
Intrathecal Baclofen (Pump)
6.5. Global Muscle Spasticity Market, Sub-Segmentation Of Botulinum Toxin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Botox (Botulinum Toxin Type A)
Dysport (Botulinum Toxin Type A)
Xeomin (Botulinum Toxin Type A)
Myobloc (Botulinum Toxin Type B)
6.6. Global Muscle Spasticity Market, Sub-Segmentation Of Diazepam, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Diazepam
Injectable Diazepam
6.7. Global Muscle Spasticity Market, Sub-Segmentation Of Dantrolene Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Dantrolene
Injectable Dantrolene
6.8. Global Muscle Spasticity Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tizanidine
Clonidine
Gabapentin
Other Muscle Relaxants
Selective Serotonin Reuptake Inhibitors (SSRIs)
7. Muscle Spasticity Market Regional And Country Analysis
7.1. Global Muscle Spasticity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Muscle Spasticity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
